Near-infrared second-region formazan dye molecule with high photo-thermal conversion efficiency, and preparation method and application of near-infrared second-region formazan dye molecule

Nanoparticles were prepared by synthesizing the near-infrared second-zone fluoroboron formazan dye molecule BDF-8OMe with high photothermal conversion efficiency and self-assembled with amphiphilic polymer, which solved the problem of scarcity of small molecule absorption in NIR-II region and achieved deep layer Accurate and efficient photothermal treatment of tumor tissue improves treatment efficiency and accuracy.

CN118894875AActive Publication Date: 2024-11-05NANJING TECH UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410922654.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-05
Estimated Expiration
2044-07-10

AI Technical Summary

Technical Problem

The existing NIR-II area has scarce and insufficient diversity of small molecules absorption species, resulting in insufficient tissue penetration in traditional tumor photodiagnosis and treatment, and it is impossible to effectively diagnose and treat tumors in deep areas.

Method used

Synthesize a near-infrared second-zone fluoroboron formazan dye molecule with high photothermal conversion efficiency, and self-assemble with amphiphilic polymer F127 to prepare nanoparticles for NIR-II photoacoustic/photothermal imaging introduction Tumor photothermal treatment.

Benefits of technology

Under 1064nm laser excitation, BDF-8OMe nanoparticles exhibit a high photothermal conversion efficiency of 62.5%, which is used for accurate and efficient photothermal treatment of deep tumor tissues, reducing treatment damage and side effects, and improving treatment efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118894875A_ABST
    Figure CN118894875A_ABST
Patent Text Reader

Abstract

The invention provides a near-infrared two-region fluorine boron formazan dye molecule with high photo-thermal conversion efficiency and a preparation method thereof, and the preparation method comprises the following steps: in a nitrogen atmosphere, dissolving BDF-2Br and N1-(4-(bis (4-methoxyphenyl) amino) phenyl)-N4, N4-bis (4-methylphenyl) benzene-1, 4-diamine (TPA-NH) in a toluene medium, carrying out a reaction by using palladium acetate as a catalyst, and carrying out a reaction at the temperature of 60-80 DEG C for 1-2 hours to obtain the near-infrared two-region fluorine boron formazan dye molecule with high photo-thermal conversion efficiency. And carrying out a reaction under the conditions of taking tritert-butylphosphine tetrafluoroborate as a ligand and taking cesium carbonate as an inorganic base to obtain the formazan dye molecule BDF-8OMe. The formazan dye molecule has a D-A-D structure and has good absorption in an NIR-II region, and the photo-thermal reagent prepared from the formazan dye molecule shows 62.5% of high photo-thermal conversion efficiency under excitation of 1064 nm laser, can be used for accurate and efficient NIR-II photo-acoustic / photo-thermal imaging mediated photo-thermal therapy of deep tumor tissues, and has good application prospects. Tumor treatment injuries and side effects are reduced, and the treatment efficiency and accuracy are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomaterials, and in particular to a near-infrared second-zone fluoroboratomethazine dye molecule with high photothermal conversion efficiency, and a preparation method and application thereof. Background Art

[0003] With the development of cancer therapeutics, NIR-II (1000-1700nm) lasers have deeper penetration depths and higher maximum permissible exposures (e.g. 0.33W cm for 808nm lasers). -2 , 1064nm laser is 1.0W cm -2 ), current research focuses more on the transition from traditional NIR-I region (700-1000nm) excitation to NIR-II region excitation.

[0004] At present, the development of NIR-II photothermal agents mainly focuses on inorganic materials (such as gold nanoparticles, copper sulfide nanomaterials, quantum dots, etc.), organic conjugated polymers, small molecule dyes, etc. Although various NIR-II photothermal agents based on inorganic materials have been developed, they still face disadvantages such as poor reproducibility and potential long-term biological toxicity. Semiconductor polymer molecules with long conjugated skeletons often show good absorbance and photothermal performance in the NIR-II region, but the uncertainty of molecular weight and molecular structure makes them still limited to the experimental research stage. In contrast, small dye molecules have fast metabolism, clear structure, high biosafety, and are more in line with the requirements of clinical transformation. At present, the development of small molecules absorbing in the NIR-II region is still concentrated on cyanine dyes, because their molecular conjugation is relatively long and the introduction of heterocycles makes it easier to expand the molecular absorption peak to the NIR-II region. However, due to limited molecular conjugation, complex synthesis, lack of stacking units, etc., NIR-II absorbing small molecules with donor-acceptor-donor (DAD) structure are still very scarce. Summary of the invention

[0005] The purpose of the present invention is to synthesize a fluoroboraneformazan dye molecule with high photothermal conversion efficiency to solve the current problems of scarcity and insufficient diversity of NIR-II absorbing small molecules, and to improve the problem of insufficient tissue penetration in traditional tumor photodiagnosis and treatment, and the inability to diagnose and treat deep tumors.

[0006] According to the first aspect of the present invention, a near-infrared second-zone fluoroborylformazan dye molecule with high photothermal conversion efficiency is provided. The fluoroborylformazan dye molecule is denoted as BDF-8OMe, and the chemical structure is shown in Formula I:

[0007]

[0008] According to a second aspect of the present invention, there is provided a method for preparing the aforementioned near-infrared second-region fluoroboraneformazan dye molecule with high photothermal conversion efficiency, comprising the following steps:

[0009] In a nitrogen atmosphere, BDF-2Br and N1-(4-(bis(4-methoxyphenyl)amino)phenyl)-N4,N4-bis(4-methylphenyl)benzene-1,4-diamine (TPA-NH) were dissolved in a toluene medium, palladium acetate was used as a catalyst, tri-tert-butylphosphine tetrafluoroborate was used as a ligand, and cesium carbonate was used as an inorganic base. The reaction was carried out under the required reaction conditions to obtain the fluoroboraneformazan dye molecule BDF-8OMe.

[0010] As an optional embodiment, the molar ratio of BDF-2Br, TPA-NH, palladium acetate, tri-tert-butylphosphine tetrafluoroborate, and cesium carbonate is 1:(2-4):(0.05-0.15):(0.15-0.45):(6-8).

[0011] As an optional embodiment, the required reaction conditions are: reacting at a temperature of 80-110° C. for 18-24 hours.

[0012] As an optional embodiment, the preparation method further comprises: after the reaction is completed, removing the solvent in the reaction mixture, and purifying the obtained crude product by column chromatography to obtain dark blue solid BDF-8OMe.

[0013] As an optional embodiment, the method for removing the solvent from the reaction mixture is: extracting the reaction mixture with dichloromethane and removing the solvent by distillation under reduced pressure.

[0014] According to a third aspect of the present invention, there is provided a use of the aforementioned near-infrared II fluoroboroformazan dye molecule with high photothermal conversion efficiency in the preparation of photothermal agents for NIR-II photoacoustic / photothermal imaging-mediated tumor photothermal therapy.

[0015] According to a fourth aspect of the present invention, there is provided a photothermal agent prepared using the aforementioned near-infrared second-zone fluoroboroformazan dye molecule with high photothermal conversion efficiency.

[0016] As an optional embodiment, the photothermal agent is a nanoparticle prepared by self-assembly of BDF-8OMe and amphiphilic polymer F127.

[0017] As an optional embodiment, the photothermal conversion efficiency of the photothermal agent under 1064nm laser excitation is above 60%.

[0018] It can be seen from the above technical scheme of the present invention that the near-infrared II fluoroborax dye molecule with high photothermal conversion efficiency proposed by the present invention has a DAD structure and has good absorption in the NIR-II region. The nanoparticles prepared by self-assembly of the fluoroborax dye molecule and the amphiphilic polymer F127 show a high photothermal conversion efficiency of 62.5% under 1064nm laser excitation, and can be used for precise and efficient NIR-II photoacoustic / photothermal imaging-mediated photothermal therapy of deep tumor tissues, reducing tumor treatment damage and side effects, and improving treatment efficiency and accuracy. As a new NIR-II small molecule photothermal agent, it has good application prospects in the precise diagnosis and treatment of cancer.

[0019] The fluoroborax dye of the present invention has a clear molecular structure, a simple synthesis process, and a low cost of synthetic raw materials. The nanoparticles prepared from the molecule have uniform particle size, good stability, and high NIR-II excitation photothermal conversion efficiency, which is higher than that of most NIR-II region absorbing small molecules reported so far. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is the synthesis reaction scheme of BDF-8OMe of the present invention.

[0021] Figure 2 The BDF-8OMe of the present invention is 1 H-NMR spectrum.

[0022] Figure 3 The BDF-8OMe of the present invention is 13 C-NMR spectrum.

[0023] Figure 4 It is the mass spectrum of BDF-8OMe of the present invention.

[0024] Figure 5 This is a dynamic light scattering particle size distribution test chart of the BDF-8OMe nanoparticles exemplified in the present invention.

[0025] Figure 6 Graph (A) is the ultraviolet absorption spectrum of the BDF-8OMe nanoparticles in water according to the present invention.

[0026] Figure 7 It is the light-to-heat conversion efficiency fitting curve of the BDF-8OMe nanoparticles exemplified in the present invention.

[0027] Figure 8 Relative survival rate of mouse breast cancer cells (4T1) incubated with different concentrations of BDF-8OMe nanoparticles for 24 h under light or dark conditions.

[0028] Fig. 9This is the NIR-II photoacoustic imaging image of the BDF-8OMe nanoparticles in the breast cancer model mouse.

[0029] Fig.10 This is a photothermal imaging image of the BDF-8OMe nanoparticles exemplified in the present invention at the tumor site of a breast cancer model mouse.

[0030] Fig.11 This is a graph showing the changes in tumor volume during the 14-day treatment of breast cancer model mice. DETAILED DESCRIPTION

[0031] In order to better understand the technical content of the present invention, specific embodiments are given and described as follows in conjunction with the accompanying drawings.

[0032] Various aspects of the present invention are described in this disclosure with reference to the accompanying drawings, in which many illustrative embodiments are shown. The embodiments of the present disclosure are not necessarily intended to include all aspects of the present invention. It should be understood that the various concepts and embodiments introduced above, as well as those described in more detail below, can be implemented in any of many ways.

[0033] Near-infrared second-region fluoroborane-formazan dye molecules with high photothermal conversion efficiency

[0034] In an exemplary embodiment of the present invention, a near-infrared second-zone fluoroborylformazan dye molecule with high photothermal conversion efficiency is provided. The fluoroborylformazan dye molecule is denoted as BDF-8OMe, and the chemical structure is shown in Formula I:

[0035]

[0036] The boroformazan dye molecule exemplified above has a donor-acceptor-donor (DAD) structure and has good absorption in the NIR-II region.

[0037] Preparation method

[0038] Combination Figure 1 As shown, the exemplary preparation method of the near-infrared second-zone fluoroborane dye molecule with high light-to-heat conversion efficiency of the present invention is to use BDF-2Br, N1-(4-(bis(4-methoxyphenyl)amino)phenyl)-N4, N4-bis(4-methylphenyl)benzene-1,4-diamine, palladium acetate, tri-tert-butylphosphine tetrafluoroborate, and cesium carbonate as raw materials, according to Figure 1 The reaction route is used for reaction preparation.

[0039] As an optional example, the preparation method specifically includes the following steps:

[0040] In a nitrogen atmosphere, BDF-2Br and N1-(4-(bis(4-methoxyphenyl)amino)phenyl)-N4,N4-bis(4-methylphenyl)benzene-1,4-diamine (TPA-NH) were dissolved in a toluene medium, palladium acetate was used as a catalyst, tri-tert-butylphosphine tetrafluoroborate was used as a ligand, and cesium carbonate was used as an inorganic base. The reaction was carried out under the required reaction conditions to obtain the fluoroboraneformazan dye molecule BDF-8OMe.

[0041] As an optional example, the molar ratio of BDF-2Br, TPA-NH, palladium acetate, tri-tert-butylphosphine tetrafluoroborate, and cesium carbonate is 1:(2-4):(0.05-0.15):(0.15-0.45):(6-8).

[0042] As an optional example, the required reaction conditions are: reacting at a temperature of 80-110° C. for 18-24 hours.

[0043] As an optional example, the preparation method further includes: after the reaction is completed, removing the solvent in the reaction mixture, and purifying the obtained crude product by column chromatography to obtain a dark blue solid BDF-8OMe.

[0044] As an optional embodiment, the method for removing the solvent from the reaction mixture is: extracting the reaction mixture with dichloromethane and removing the solvent by distillation under reduced pressure.

[0045] In another exemplary embodiment of the present invention, there is also provided an application of the aforementioned near-infrared II fluoroboroformazan dye molecule with high photothermal conversion efficiency in the preparation of photothermal agents for NIR-II photoacoustic / photothermal imaging-mediated tumor photothermal therapy.

[0046] In another exemplary embodiment of the present invention, a photothermal agent prepared using the aforementioned near-infrared second-zone fluoroboratomethazine dye molecule with high photothermal conversion efficiency is also provided.

[0047] In a preferred embodiment, the photothermal agent is nanoparticles prepared by self-assembly of BDF-8OMe and amphiphilic polymer F127.

[0048] In a preferred embodiment, the photothermal conversion efficiency of the photothermal agent under 1064 nm laser excitation is above 60%.

[0049] The photothermal agent prepared using the aforementioned near-infrared II fluoroboratomethazine dye molecule with high photothermal conversion efficiency exhibits a high photothermal conversion efficiency of 62.5% under 1064nm laser excitation, and can be used for precise and efficient NIR-II photoacoustic / photothermal imaging-mediated photothermal therapy of deep tumor tissues, reducing tumor treatment damage and side effects and improving treatment efficiency and accuracy.

[0050] For better understanding, the present invention is further described below in conjunction with several specific examples, but the preparation process is not limited thereto, and the content of the present invention is not limited thereto.

[0051] Unless otherwise specified, the materials in the examples were prepared according to existing methods or directly purchased from the market.

[0052] Example 1

[0053] [Synthesis of BDF-8OMe]

[0054] In a dry 250 mL double-necked flask, BDF-2Br (227.43 mg, 0.5 mmol), N1-(4-(bis(4-methoxyphenyl)amino)phenyl)-N4,N4-bis(4-methylphenyl)benzene-1,4-diamine (935.63 mg, 1.5 mmol), palladium acetate (11.2 mg, 0.05 mmol), tri-tert-butylphosphine tetrafluoroborate (43.5 mg, 0.15 mmol), cesium carbonate (1140 mg, 3.5 mmol), anhydrous dry toluene (30 mL) were added, and the mixture was heated to 110° C. in a nitrogen atmosphere in the dark. After reacting for 20 hours, the mixture was cooled to room temperature, and the reaction mixture was extracted with dichloromethane. The solvent was removed by distillation under reduced pressure, and the crude product was purified by column chromatography (silicon dioxide, dichloromethane: petroleum ether = 4:1) to give a dark blue solid BDF-8OMe (110 mg, 14.3%).

[0055] like Figure 2 As shown, 1 H NMR (400MHz, CDCl3): δppm 7.72 (d, J = 8.8Hz, 4H), 7.07 (d, J = 8.9Hz, 16H), 6.95 (t, J = 10.0Hz, 12H), 6.85 (dd, J = 11.7, 8.9Hz, 24H), 3.79 (s, 24H).

[0056] like Figure 3 As shown, 13 C NMR (100MHz, CDCl3): δppm 156.00,150.43,146.22,140.80,138.29,126.96,126.67,124.04,121.21,119.01,115.51,114.82,100.00,55.61.

[0057] like Figure 4 As shown, MALDI-TOF mass spectrum (m / z):calcd for C 94 H 80 BF2N 11 O8[M]+ :1539.6252; found,1540.0940.

[0058] Combination Figure 2-4 As shown, the molecular structure of BDF-8OMe can be determined to be Formula I.

[0059]

[0060] Example 2

[0061] [Preparation of BDF-8OMe nanoparticles]

[0062] BDF-8OMe nanoparticles were prepared by nanoprecipitation method as follows:

[0063] BDF-8OMe molecules (1 mg) (prepared according to the method of Example 1) and Pluronic F-127 (10 mg) were dissolved in tetrahydrofuran (1 mL) and sonicated for 5 minutes.

[0064] Then, the solution was quickly injected into deionized water (10 mL) and ultrasonicated for 1 hour. After stirring and volatilizing to completely remove tetrahydrofuran, it was filtered with a 0.22 μm filter to obtain a clear and transparent dark blue BDF-8OMe nanoparticle solution, which was stored at 4° C. for future use.

[0065] like Figure 5 As shown in FIG. 1 , the dynamic light scattering particle size distribution test results of BDF-8OMe nanoparticles show that the hydrated particle size is 80 nm, which meets the requirements of enhanced permeability and retention (EPR) effect.

[0066] like Figure 6 As shown, BDF-8OMe nanoparticles have a maximum absorption peak at 903 nm in water, and the absorption peak tail extends to 1300 nm.

[0067] Example 3

[0068] [Photothermal performance test of BDF-8OMe nanoparticles]

[0069] The 1064 nm laser (1 W cm -2 ) was irradiated with BDF-8OMe nanoparticle aqueous solution (1 mL, 100 μg / mL) and deionized water (1 mL). After heating for 10 minutes, it was naturally cooled for 15 minutes to return to room temperature. The photothermal conversion efficiency of the BDF-8OMe nanoparticle aqueous solution was calculated using the cooling section.

[0070] like Figure 7As shown, the photothermal conversion efficiency of the BDF-8OMe nanoparticle aqueous solution of the present invention is 62.5%.

[0071] Example 4

[0072] [Cytotoxicity experiment of BDF-8OMe nanoparticles]

[0073] 4T1 cells were plated at 5.0 × 10 3 The density of each cell was inoculated in two 96-well cell culture plates and incubated at 37°C in a dark environment with 5% CO2 for 24 hours. Different concentrations of BDF-8OMe nanoparticles (0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 μg mL -1 ) were added to the well plate and incubated for 12 h.

[0074] After 12 hours of incubation, the cells were illuminated with a 1064 nm laser (1 W cm -2 ) One of the wells was irradiated for 5 min per well, and the other well was incubated in the dark to test the dark cytotoxicity of BDF-8OMe nanoparticles.

[0075] After the illumination is completed, the plate is incubated in the dark for 12 hours, and then 200 μL of MTT solution is added to each well and incubated in the dark for 4 hours. The plate culture medium is removed, 200 μL of dimethyl sulfoxide is added to dissolve the blue-purple formazan crystals, and the absorbance value at 490 nm is read with an ELISA reader to calculate the survival rate of 4T1 cells under different concentrations of BDF-8OMe nanoparticles. The cell survival rate is calculated as follows: average absorbance of the treatment group / average absorbance of the control group × 100%.

[0076] like Figure 8 As shown in Figure 2, under dim light, even at a concentration of 50 μg mL -1 , the survival rate of 4T1 cells can still be maintained above 90%; however, under light conditions, only 35 μg mL -1 BDF-8OMe nanoparticles can kill nearly 90% of 4T1 cells.

[0077] Example 5

[0078] [NIR-II photoacoustic imaging of BDF-8OMe nanoparticles in mice]

[0079] BDF-8OMe nanoparticles (200 μL, 500 μg mL -1 ) was injected into mice through the tail vein, and the photoacoustic images of the tumor site were recorded at different time points (pre, 2, 4, 6, 8, 12, and 18 hours before injection).

[0080] like Fig. 9 As shown, after mice were intravenously injected with BDF-8OMe nanoparticles, the photoacoustic signal at the tumor site gradually increased with time, reaching a maximum value at 8 hours, and then gradually weakened.

[0081] Example 6

[0082] [Photothermal imaging of BDF-8OMe nanoparticles in mice]

[0083] BDF-8OMe nanoparticles (100 μL, 500 μg mL -1 ) or PBS buffer (100 μL) was injected into mice through the tail vein, and the photothermal images of the tumor site at different time points (0, 1, 2, 3, 4, and 5 minutes) were recorded. Fig.10 shown.

[0084] Example 7

[0085] [Tumor treatment experiment of BDF-8OMe nanoparticles]

[0086] 4T1 cancer cells were injected subcutaneously to establish a 4T1 tumor-bearing mouse model. When the tumor volume reached 50 mm 3 After that, you can carry out subsequent experiments.

[0087] The 4T1 tumor-bearing mice were randomly divided into 4 groups (PBS, PBS+L, NPs, and NPs+L, 5 mice in each group, L represents laser irradiation). The mice in the PBS group and the PBS+L group were intravenously injected with PBS (100 μL), and the mice in the NPs group and the NPs+L group were intravenously injected with BDF-8OMe nanoparticles (100 μL, 500 μg mL -1 ). 6 h after injection, the tumor sites of mice in the PBS+L group and NPs+L group were illuminated with 1064 nm laser (1 W cm -2 ) for 5 minutes. After one treatment, the tumor size was measured every 2 days until the 14th day.

[0088] like Fig.11 As shown in the figure, after one treatment, the tumor in the NPs+L group was completely eliminated on the 4th day after treatment and there was no recurrence within 14 days, while the tumor volume in the PBS group, PBS+L group and NPs group increased by 7 to 8 times on the 14th day after treatment.

[0089] Combined with the above tests, it can be proved that the photothermal agent prepared by the fluoroborax dye molecule of the present invention can be used for accurate and efficient NIR-II photoacoustic / photothermal imaging-mediated photothermal therapy of deep tumor tissues, reducing tumor treatment damage and side effects, and improving treatment efficiency and accuracy.

[0090] Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. A person with ordinary knowledge in the technical field to which the present invention belongs may make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be determined by the definition of the claims.

Claims

1. A near-infrared second-zone fluoroborane-formazan dye molecule with high photothermal conversion efficiency, It is characterized in that The fluoroboraneformazan dye molecule is denoted as BDF-8OMe, and its chemical structure is shown in Formula I:

2. A method for preparing the near-infrared second-region fluoroboraneformazan dye molecule with high photothermal conversion efficiency as claimed in claim 1, It is characterized in that The following steps are involved: In a nitrogen atmosphere, BDF-2Br and N1-(4-(bis(4-methoxyphenyl)amino)phenyl)-N4,N4-bis(4-methylphenyl)benzene-1,4-diamine (TPA-NH) were dissolved in a toluene medium, palladium acetate was used as a catalyst, tri-tert-butylphosphine tetrafluoroborate was used as a ligand, and cesium carbonate was used as an inorganic base. The reaction was carried out under the required reaction conditions to obtain the fluoroboraneformazan dye molecule BDF-8OMe.

3. The preparation method according to claim 2, It is characterized in that The molar ratio of BDF-2Br, TPA-NH, palladium acetate, tri-tert-butylphosphine tetrafluoroborate, and cesium carbonate is 1:(2-4):(0.05-0.15):(0.15-0.45):(6-8).

4. The preparation method according to claim 2, It is characterized in that The required reaction conditions are: reacting at a temperature of 80-110°C for 18-24h.

5. The preparation method according to claim 2, It is characterized in that The preparation method further comprises: after the reaction is completed, removing the solvent in the reaction mixture, and purifying the obtained crude product by column chromatography to obtain dark blue solid BDF-8OMe.

6. The preparation method according to claim 5, It is characterized in that The method for removing the solvent from the reaction mixture is: extracting the reaction mixture with dichloromethane and removing the solvent by distillation under reduced pressure.

7. Use of the near-infrared II fluoroboratomethazine dye molecule with high photothermal conversion efficiency as claimed in claim 1 in the preparation of a photothermal agent for NIR-II photoacoustic / photothermal imaging-mediated tumor photothermal therapy.

8. A photothermal agent prepared using the near-infrared second-zone fluoroboraxyl dye molecule with high photothermal conversion efficiency as claimed in claim 1.

9. The photothermal reagent according to claim 8, It is characterized in that The photothermal agent is a nanoparticle prepared by self-assembly of BDF-8OMe and amphiphilic polymer F127.

10. The photothermal agent according to claim 8, It is characterized in that The photothermal conversion efficiency of the photothermal reagent under 1064nm laser excitation is above 60%.

Citation Information

Patent Citations

  • Fluoro-boron formazan near-infrared-II fluorescent dye, preparation method and application

    CN113072574A

  • Azo compounds for type i phototherapy

    US20020164287A1